KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Profit After Tax (2019 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Profit After Tax for 7 consecutive years, with $210.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Profit After Tax rose 14651.15% year-over-year to $210.8 million, compared with a TTM value of $287.2 million through Dec 2025, up 4893.08%, and an annual FY2025 reading of $287.2 million, up 4893.08% over the prior year.
  • Profit After Tax was $210.8 million for Q4 2025 at Aurinia Pharmaceuticals, up from $31.6 million in the prior quarter.
  • Across five years, Profit After Tax topped out at $210.8 million in Q4 2025 and bottomed at -$50.4 million in Q1 2021.
  • Average Profit After Tax over 5 years is -$3.7 million, with a median of -$12.5 million recorded in 2023.
  • The sharpest move saw Profit After Tax plummeted 94.27% in 2021, then soared 14651.15% in 2025.
  • Year by year, Profit After Tax stood at -$33.3 million in 2021, then increased by 21.84% to -$26.0 million in 2022, then fell by 3.18% to -$26.9 million in 2023, then skyrocketed by 105.32% to $1.4 million in 2024, then skyrocketed by 14651.15% to $210.8 million in 2025.
  • Business Quant data shows Profit After Tax for AUPH at $210.8 million in Q4 2025, $31.6 million in Q3 2025, and $21.5 million in Q2 2025.